TVTX
Travere Therapeutics, Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $8.53 | $43 | +403% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $8.53 | $43 | +403% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $8.53 | $43 | +403% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $8.53 | $43 | +403% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $8.53 | $43 | +403% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management 2× in & out | Q4 2025 | Q2 2026 | — | +0% |
| Point72 Asset Management 5× in & out | Q1 2026 | Q2 2026 | → $43 | +48% |
| Viking Global Investors | Q1 2025 | Q3 2025 | → $18 | -20% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Travere Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 21, 2026 — the most recent Form 4 on file — not from today.
- Form 40001344381-26-000004May 21, 2026
- Form 40001454001-26-000002May 21, 2026
- Form 40001619622-26-000002May 21, 2026
- Form 40001477384-26-000008May 21, 2026
- Form 40001506916-26-000003May 21, 2026
- Form 40001123343-26-000004May 21, 2026
- Form 40001376043-26-000006May 21, 2026
- Form 40001517790-26-000002May 21, 2026
- Form 40001680739-26-000012May 21, 2026
- Form 40001376043-26-000005May 19, 2026
- Form 40001680739-26-000008May 6, 2026
- Form 40001506916-26-000001May 6, 2026
- Form 40001698262-26-000004May 6, 2026
- Form 40001283303-26-000009May 6, 2026
- Form 40001902368-26-000006May 6, 2026
Fundamentals
XBRL · Travere Therapeutics, Inc.Annual figures sourced directly from Travere Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Travere Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 2, 2026
- 8-KMaterial eventMay 21, 2026
- 8-KMaterial eventMay 11, 2026
- 10-QQuarterly reportMay 4, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventApr 14, 2026
- DEF 14AProxy statementApr 6, 2026
- 10-KAnnual reportFeb 19, 2026
- 8-KMaterial eventFeb 19, 2026
- 8-KMaterial eventJan 13, 2026
- 8-KMaterial eventJan 12, 2026
- 10-QQuarterly reportOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 8-KMaterial eventSep 10, 2025
- 10-QQuarterly reportAug 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $0.00 | — | +0% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $29 | $43 | +48% |
| Millennium Management | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| Point72 Asset Management | Q4 2025 | Q2 2026 | $0.00 | — | +0% |
| Point72 Asset Management | Q3 2025 | Q4 2025 | $18 | $35 | +89% |
| Viking Global Investors | Q1 2025 | Q3 2025 | $23 | $18 | -20% |
| Citadel Advisors | Q3 2024 | open | $8.53 | $43 | +403% |
| Two Sigma Investments | Q3 2024 | open | $8.53 | $43 | +403% |
| D.E. Shaw | Q3 2024 | open | $8.53 | $43 | +403% |
| D.E. Shaw | Q3 2024 | open | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $8.53 | $43 | +403% |
| Millennium Management | Q3 2024 | Q2 2026 | $8.53 | $43 | +399% |
| Point72 Asset Management | Q3 2024 | Q4 2024 | $8.53 | $18 | +117% |
| Point72 Asset Management | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2024 | open | $8.53 | $43 | +403% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.